|

Paclitaxel (albumin-bound) Clinical Trials

3 actively recruiting trials

▼ -1 trial since August 2026

Pipeline

Phase 2: 2Phase 1/2: 1

Top Sponsors

  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd1
  • Dai, Guanghai1
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Indications

  • Cancer3
  • Metastatic HER2-Negative Breast Cancer1
  • Inoperable Locally Advanced HER2-Negative Breast Cancer1
  • Recurrent or Metastatic1
  • TP53 Mutation1

Other3 trials

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Phase 2
Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
Phase 2
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.